期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 195, 期 12, 页码 1575-1584出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20020072
关键词
angiogenesis; antibody; cytotoxic T lymphocytes; cancer vaccine; tumor antigen
资金
- NCI NIH HHS [CA86649-01] Funding Source: Medline
The vascular endothelial growth factor (VEGF) receptor fetal liver kinase 1 (flk1: VEGFR-2, KDR) is an endothelial cell-specific receptor tyrosine kinase that mediates physiological and pathological angiogenesis. We hypothesized that an active immunotherapy approach targeting flk1 may inhibit tumor angiogenesis and metastasis. To test this hypothesis, we first evaluated whether immune responses to flk1 could be elicited in mice by immunization with dendritic cells pulsed with a soluble flk1 protein (DC-flk1). This immunization generated flk1-specific neutralizing antibody and CD8(+) cytotoxic T cell responses, breaking tolerance to self-flk1 antigen. Tumor-induced angiogenesis was suppressed in immunized mice as measured in an alginate bead assay. Development of pulmonary metastases was strongly inhibited in DC-flk1-immunized mice challenged with B16 melanoma or Lewis lung carcinoma cells. DC-flk1 immunization also significantly prolonged the survival of mice challenged with Lewis lung tumors. Thus, an active immunization strategy that targets an angiogenesis-related antigen on endothelium can inhibit angiogenesis and may be a useful approach for treating angiogenesis-related diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据